AR102778A1 - Composición farmacéutica, su preparación y sus usos - Google Patents

Composición farmacéutica, su preparación y sus usos

Info

Publication number
AR102778A1
AR102778A1 ARP150103846A ARP150103846A AR102778A1 AR 102778 A1 AR102778 A1 AR 102778A1 AR P150103846 A ARP150103846 A AR P150103846A AR P150103846 A ARP150103846 A AR P150103846A AR 102778 A1 AR102778 A1 AR 102778A1
Authority
AR
Argentina
Prior art keywords
compound
interest
pharmaceutical composition
typically
subject
Prior art date
Application number
ARP150103846A
Other languages
English (en)
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of AR102778A1 publication Critical patent/AR102778A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Abstract

Composición farmacéutica que comprende la combinación de (i) al menos una nanopartícula biocompatible, donde dicha nanopartícula biocompatible comprende al menos un oligómero de albúmina (n ³ 2) o que consiste en un oligómero de albúmina y de (ii) al menos un compuesto de interés, tipicamenel al menos un compuesto farmacéutico, por ejemplo un anticuerpo, para administrar a un sujeto que necesita de dicho al menos un compuesto de interés, en donde la al menos una nanopartícula potencia la eficacia de al menos un compuesto de interés. La dimensión más larga de la nanopartícula biocompatible está típicamente entre aproximadamente 4 y aproximadamente 500 nm. Composición para usar para la administración del al menos un compuesto de interés a un sujeto que lo necesita, en donde la al menos una nanopartícula biocompatible y el al menos un compuesto de interés se han de administrar a dicho sujeto de modo secuencial, típicamente entre más de 5 minutos y aproximadamente 72 horas entre sí.
ARP150103846A 2014-11-25 2015-11-24 Composición farmacéutica, su preparación y sus usos AR102778A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14306871 2014-11-25

Publications (1)

Publication Number Publication Date
AR102778A1 true AR102778A1 (es) 2017-03-22

Family

ID=52013979

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103846A AR102778A1 (es) 2014-11-25 2015-11-24 Composición farmacéutica, su preparación y sus usos

Country Status (11)

Country Link
US (2) US20170258937A1 (es)
EP (1) EP3229843B1 (es)
JP (1) JP6722688B2 (es)
AR (1) AR102778A1 (es)
DK (1) DK3229843T3 (es)
ES (1) ES2774365T3 (es)
LT (1) LT3229843T (es)
PL (1) PL3229843T3 (es)
PT (1) PT3229843T (es)
TW (1) TW201628644A (es)
WO (1) WO2016083331A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102245421B1 (ko) 2013-05-30 2021-04-29 큐라디즘 약학적 조성물, 이의 제조방법 및 이의 용도
PL3223796T3 (pl) 2014-11-25 2021-12-20 Curadigm Sas Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
UA123665C2 (uk) 2014-11-25 2021-05-12 Кюрадігм Сас Фармацевтична композиція, її одержання і застосування
EP3302419A1 (en) 2015-05-28 2018-04-11 Nanobiotix Nanoparticles for use as a therapeutic vaccine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT75469A (en) 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
RU2006101216A (ru) * 2003-08-01 2007-07-20 Амген Инк. (US) Кристаллические полипептиды 2 фактора некроза опухолей
EP1701745B1 (en) 2003-12-22 2014-12-10 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
US20090130050A1 (en) 2006-03-24 2009-05-21 Toto Ltd. Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2280601A4 (en) 2008-02-21 2012-08-29 Sequoia Pharmaceuticals Inc AMINO ACID HEMMER OF CYTOCHROM P450
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2010048623A2 (en) * 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
JP5649137B2 (ja) 2010-02-17 2015-01-07 国立大学法人神戸大学 放射線治療剤
MX359413B (es) * 2010-03-26 2018-09-27 Abraxis Bioscience Llc Metodos de tratamiento de carcinoma hepatocelular.
WO2012051220A1 (en) * 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
WO2012104277A2 (en) 2011-01-31 2012-08-09 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
CN103429227B (zh) 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
US8859499B2 (en) 2012-03-20 2014-10-14 Albert Einstein College Of Medicine Of Yeshiva University Method of enhancing efficacy of blood transfusions
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
KR102245421B1 (ko) 2013-05-30 2021-04-29 큐라디즘 약학적 조성물, 이의 제조방법 및 이의 용도
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
UA123665C2 (uk) 2014-11-25 2021-05-12 Кюрадігм Сас Фармацевтична композиція, її одержання і застосування
MX2017006813A (es) 2014-11-25 2018-01-30 Nanobiotix Composicion farmaceutica, preparacion y usos de la misma.
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
PL3223796T3 (pl) 2014-11-25 2021-12-20 Curadigm Sas Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania

Also Published As

Publication number Publication date
JP2017538782A (ja) 2017-12-28
US20170258937A1 (en) 2017-09-14
ES2774365T3 (es) 2020-07-20
US11191846B2 (en) 2021-12-07
US20180339062A1 (en) 2018-11-29
WO2016083331A1 (en) 2016-06-02
EP3229843B1 (en) 2020-01-01
JP6722688B2 (ja) 2020-07-15
LT3229843T (lt) 2020-05-25
EP3229843A1 (en) 2017-10-18
TW201628644A (zh) 2016-08-16
PL3229843T3 (pl) 2020-06-29
PT3229843T (pt) 2020-03-06
DK3229843T3 (da) 2020-03-09

Similar Documents

Publication Publication Date Title
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR102779A1 (es) Composición farmacéutica, su preparación y sus usos
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
PE20151759A1 (es) Imidazopiridazinas sustituidas
DOP2016000007A (es) Pirazolpiridinas sustituidas
UY35905A (es) Inhibidores del transporte de glucosa
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
AR102782A1 (es) Composición farmacéutica, su preparación y sus usos
UY37538A (es) Amidas aromáticas de ácidos carboxílicos
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
BR112014016804A8 (pt) composições, métodos de uso e métodos de tratamento
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
ECSP19024033A (es) Composiciones de tesofensina
AR108792A1 (es) Composiciones que comprenden timolol

Legal Events

Date Code Title Description
FB Suspension of granting procedure